Preclinical Capabilities

Optimal CAR-T Study Design to Advance Your Therapeutic Program.

Trusted immuno-oncology models.

TD2 is your trusted, experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy studies. Our extensive knowledge of CAR-T in both solid and hematologic tumors enables optimal study design and rapid study initiation.

Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Having performed more than 100 studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.

TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability. See available cell lines


TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR-T cell mouse studies across multiple antigen targets in a number of oncology indications.

  • Dr. Jon TerrettHead of Immuno-Oncology Research and Translation CRISPR Therapeutics

Learn more about our CAR-T services.

Contact our experts to help advance your adoptive cell therapy with our trusted preclinical research services.

    Immuno-oncology

    Comprehensive preclinical services for immuno-oncology.

    TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.

    Large panel of human and murine tumor models

    Syngeneic mouse models


    • Fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors

    Humanized mice


    • Human PBMCs or effector cell engraftment
    • Sourced CD34+ humanized mice

    Immuno-therapy Models

    Syngeneic models.

    Syngeneic tumor models are fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors.

    One Consistent Host — through 16S ribosomal RNA (rRNA) gene sequencing launched before the study even begins, we define the microbiome at the onset, which enables your project focused access to a known and stable host from start to finish.

    Find Effector Cells — through multi-parameter flow cytometry, we can characterize phenotypic immune cell population changes post-treatment.
    See available models

    E0771 Murine Breast Tumor Model

    E0771 Murine Breast Tumor Model

    MC38 Murine Colon Tumor Model

    MC38 Murine Colon Tumor Model

    CT-26 Murine Colon Tumor Model

    CT-26 Murine Colon Tumor Model

    Get Started

    Work with a team who believes in your research as much as you do.

    Are you ready to start your preclinical Adoptive Cell Transfer Therapy studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.